Vera Therapeutics (VERA) Cash from Financing Activities (2020 - 2026)

Vera Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 157.14% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $311.3 million (down 6.14% YoY) and the FY2025 annual result came in at $308.9 million, down 49.08% from the prior year.
• Cash from Financing Activities was $3.9 million for Q1 2026 at Vera Therapeutics, down from $286.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $326.0 million in Q4 2024 and bottomed at $48000.0 in Q2 2022.
• A 5-year average of $67.9 million and a median of $3.9 million in 2026 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 286771.43% in 2022, while the deepest fall reached 99.9% in 2022.
• Vera Therapeutics' Cash from Financing Activities stood at $20.7 million in 2022, then rose by 19.89% to $24.8 million in 2023, then surged by 1212.85% to $326.0 million in 2024, then slipped by 12.17% to $286.3 million in 2025, then sank by 98.62% to $3.9 million in 2026.
• Business Quant data shows VERA's Cash from Financing Activities at $3.9 million in Q1 2026, $286.3 million in Q4 2025, and $797000.0 in Q3 2025.